OCGN Ocugen, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1372299 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.3%
TTM net income YoY-24.7%
TTM EPS YoY-11.2%
Revenue 3-yr CAGR22.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,483.9%
Net margin-1,605.2%
FCF margin-1,334.3%
EBITDA margin-1,430.1%
Returns
ROE-660.0%
ROA-118.1%
ROIC (approx.)-1,221.1%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets89.8%
Debt / equity5.03x
Current ratio1.86x
Interest coverage-12.62x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.95M | $1.49M | $1.53M | -$193,000 | $1.75M | $1.37M | $1.48M | $764,000 |
| R&D expense | $12.50M | $10.69M | $11.26M | $10.67M | $11.15M | $8.40M | $9.53M | $8.29M |
| SG&A expense | $7.20M | $7.24M | $8.12M | $6.13M | $8.23M | $6.77M | $6.45M | $6.31M |
| Operating income | -$17.75M | -$16.44M | -$17.84M | -$17.00M | -$17.62M | -$13.79M | -$14.50M | -$13.84M |
| Interest expense | $3.09M | $4.48M | $1.32M | $1.33M | $1.31M | $1.28M | $1.26M | $601,000 |
| Net income | -$3.60M | -$24.88M | -$19.18M | -$17.71M | -$20.05M | -$14.74M | -$15.35M | -$13.88M |
| EBITDA | -$17.25M | -$15.84M | -$17.24M | -$16.39M | -$17.02M | -$13.20M | -$13.90M | — |
| EPS (basic) | -0.01 | -0.07 | -0.06 | — | -0.07 | -0.05 | -0.05 | — |
| EPS (diluted) | -0.01 | -0.07 | -0.06 | — | -0.07 | -0.05 | -0.05 | — |
| Weighted avg. shares (diluted) | 339.21M | 338.68M | 327.54M | — | 304.00M | 292.07M | 292.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $24.63M | $100.05M | $31.90M | $18.57M | $32.88M | $27.01M | $38.11M | $58.82M |
| Short-term investments | $59.62M | — | — | $0 | — | — | — | — |
| Current assets | $91.43M | $106.72M | $38.55M | $24.34M | $37.64M | $32.88M | $43.96M | $61.68M |
| PP&E, net | $12.71M | $13.35M | $13.83M | $14.39M | $14.95M | $15.45M | $15.99M | $16.55M |
| Total assets | $108.06M | $124.21M | $56.91M | $43.52M | $57.60M | $53.59M | $64.46M | $82.44M |
| Current liabilities | $118.90M | $133.08M | $20.71M | $23.04M | $20.36M | $17.99M | $16.89M | $21.59M |
| Short-term debt | $35,000 | $20,000 | $5.00M | $1.25M | $0 | $0 | $0 | $1.33M |
| Long-term debt | $1.74M | $1.73M | $24.19M | $27.54M | $28.40M | $28.02M | $27.67M | $27.34M |
| Total debt | $1.78M | $1.75M | $29.19M | $28.79M | $28.40M | $28.02M | $27.67M | $28.67M |
| Total liabilities | $125.74M | $140.76M | $51.10M | $55.68M | $54.06M | $50.54M | $48.55M | $52.81M |
| Shareholders' equity | -$17.68M | -$16.56M | $5.80M | -$12.17M | $3.53M | $3.05M | $15.91M | $29.63M |
| Net debt | -$22.85M | -$98.30M | -$2.71M | $10.22M | -$4.48M | $1.01M | -$10.44M | -$30.15M |
| Shares outstanding | 339.31M | 339.04M | 338.32M | 312.38M | 312.32M | 292.19M | 292.03M | 291.37M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.74M | -$12.20M | -$21.79M | -$13.96M | -$12.92M | -$10.73M | -$19.36M | -$10.36M |
| Capital expenditure | $149,000 | $21,000 | $6,000 | $35,000 | $91,000 | $43,000 | $16,000 | $13,000 |
| Free cash flow | -$15.89M | -$12.22M | -$21.80M | -$14.00M | -$13.01M | -$10.77M | -$19.37M | -$10.38M |
| Investing cash flow | -$59.77M | -$21,000 | -$6,000 | -$35,000 | -$86,000 | -$88,000 | -$102,000 | -$13,000 |
| Financing cash flow | $161,000 | $80.37M | $34.98M | $2,000 | $18.51M | $61,000 | -$1.25M | $30.17M |
| Depreciation & amortization | $500,000 | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 | — |
| Stock-based compensation | $1.96M | $1.83M | $3.40M | $2.00M | $1.98M | $1.84M | $1.89M | $1.88M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.